- Home
- FGI vs MYNZ Comparison
FGI vs MYNZ Comparison
Compare FGI & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FGI | MYNZ |
|---|---|---|
| Founded | 1987 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 8.8M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FGI | MYNZ |
|---|---|---|
| Price | $6.43 | $1.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 77.8K | ★ 195.9K |
| Earning Date | 11-14-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $135,654,095.00 | $659,935.00 |
| Revenue This Year | $3.80 | N/A |
| Revenue Next Year | $6.26 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.66 | N/A |
| 52 Week Low | $2.28 | $0.92 |
| 52 Week High | $12.62 | $8.20 |
Technical Indicators
Market Signals| Indicator | FGI | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 53.19 |
| Support Level | $5.51 | $1.09 |
| Resistance Level | $7.41 | $1.29 |
| Average True Range (ATR) | 1.20 | 0.10 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 24.73 | 60.56 |
Price Performance
Historical ComparisonAbout FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.